Skip to main content

Table 2 Pharmacokinetic parameters in our eighteen patients

From: Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study

Parameter

Valuea

Gefitinib

AUC0–48 (μM h)

9.49 ± 3.5

AUC0–24 (μM h)

6.17 ± 1.9

CL/F (L/h)

51.0 ± 25

Tmax (h)

4.56 ± 1.3

Cmax (μM)

0.492 ± 0.19

t1/2 (h)

24.1 ± 8.6

O-desmethyl gefitinib

AUC0–48 (μM h)

10.6 ± 14

AUC0–24 (μM h)

5.16 ± 6.7

  1. AUC0–48, area under the plasma concentration–time curve from 0 to 48 h; AUC0–24, area under the plasma concentration–time curve from 0 to 24 h; CL/F, clearance of the drug from plasma; Tmax, time to the maximum plasma concentration; Cmax, maximum plasma concentration; t1/2, the elimination half-life
  2. aMean ± SD
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us